Literature DB >> 28453388

Susceptibility of ATM-deficient pancreatic cancer cells to radiation.

Michael Ayars1, James Eshleman1,2, Michael Goggins1,2,3.   

Abstract

Ataxia telangiectasia mutated (ATM) is inactivated in a significant minority of pancreatic ductal adenocarcinomas and may be predictor of treatment response. We determined if ATM deficiency renders pancreatic cancer cells more sensitive to fractionated radiation or commonly used chemotherapeutics. ATM expression was knocked down in three pancreatic cancer cell lines using ATM-targeting shRNA. Isogenic cell lines were tested for sensitivity to several chemotherapeutic agents and radiation. DNA repair kinetics were analyzed in irradiated cells using the comet assay. We find that while rendering pancreatic cancer cells ATM-deficient did not significantly change their sensitivity to several chemotherapeutics, it did render them exquisitely sensitized to radiation. Pancreatic cancer ATM status may help predict response to radiotherapy.

Entities:  

Keywords:  ATM; pancreatic cancer; radiosensitivity

Mesh:

Substances:

Year:  2017        PMID: 28453388      PMCID: PMC5462076          DOI: 10.1080/15384101.2017.1312236

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  44 in total

1.  Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients.

Authors:  Chunling Hu; Steven N Hart; William R Bamlet; Raymond M Moore; Kannabiran Nandakumar; Bruce W Eckloff; Yean K Lee; Gloria M Petersen; Robert R McWilliams; Fergus J Couch
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-10-19       Impact factor: 4.254

2.  Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis.

Authors:  Haeryoung Kim; Burcu Saka; Spencer Knight; Michael Borges; Erica Childs; Alison Klein; Christopher Wolfgang; Joseph Herman; Volkan N Adsay; Ralph H Hruban; Michael Goggins
Journal:  Clin Cancer Res       Date:  2014-01-31       Impact factor: 12.531

3.  Enhanced sensitivity to camptothecin in ataxia-telangiectasia cells and its relationship with the expression of DNA topoisomerase I.

Authors:  P J Smith; T A Makinson; J V Watson
Journal:  Int J Radiat Biol       Date:  1989-02       Impact factor: 2.694

4.  ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates radioresistance in pancreatic cancer cells.

Authors:  Lidong Wang; Huibin Yang; Phillip L Palmbos; Gina Ney; Taylor Ann Detzler; Dawn Coleman; Jacob Leflein; Mary Davis; Min Zhang; Wenhua Tang; J Kevin Hicks; Corey M Helchowski; Jayendra Prasad; Theodore S Lawrence; Liang Xu; Xiaochun Yu; Christine E Canman; Mats Ljungman; Diane M Simeone
Journal:  Cancer Res       Date:  2014-01-27       Impact factor: 12.701

5.  Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.

Authors:  Michael D Chuong; Gregory M Springett; Jessica M Freilich; Catherine K Park; Jill M Weber; Eric A Mellon; Pamela J Hodul; Mokenge P Malafa; Kenneth L Meredith; Sarah E Hoffe; Ravi Shridhar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-04-05       Impact factor: 7.038

6.  Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.

Authors:  Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860

7.  ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.

Authors:  Maria Saveria Gilardini Montani; Andrea Prodosmo; Venturina Stagni; Dania Merli; Laura Monteonofrio; Veronica Gatti; Maria Pia Gentileschi; Daniela Barilà; Silvia Soddu
Journal:  J Exp Clin Cancer Res       Date:  2013-11-19

8.  ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.

Authors:  Marwan Kwok; Nicholas Davies; Angelo Agathanggelou; Edward Smith; Ceri Oldreive; Eva Petermann; Grant Stewart; Jeff Brown; Alan Lau; Guy Pratt; Helen Parry; Malcolm Taylor; Paul Moss; Peter Hillmen; Tatjana Stankovic
Journal:  Blood       Date:  2015-11-12       Impact factor: 22.113

9.  Exome sequencing identifies nonsegregating nonsense ATM and PALB2 variants in familial pancreatic cancer.

Authors:  Robert C Grant; Wigdan Al-Sukhni; Ayelet E Borgida; Spring Holter; Zaheer S Kanji; Treasa McPherson; Emily Whelan; Stefano Serra; Quang M Trinh; Vanya Peltekova; Lincoln D Stein; John D McPherson; Steven Gallinger
Journal:  Hum Genomics       Date:  2013-04-05       Impact factor: 4.639

10.  Comparison of EUS-guided tissue acquisition using two different 19-gauge core biopsy needles: a multicenter, prospective, randomized, and blinded study.

Authors:  John DeWitt; Chang-Min Cho; Jingmei Lin; Mohammad Al-Haddad; Marcia Irene Canto; Ashley Salamone; Ralph H Hruban; Ahmed A Messallam; Mouen A Khashab
Journal:  Endosc Int Open       Date:  2015-06-24
View more
  12 in total

1.  Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy.

Authors:  Qiang Zhang; Michael D Green; Weiping Zou; Meredith A Morgan; Xueting Lang; Jenny Lazarus; Joshua D Parsels; Shuang Wei; Leslie A Parsels; Jiaqi Shi; Nithya Ramnath; Daniel R Wahl; Marina Pasca di Magliano; Timothy L Frankel; Ilona Kryczek; Yu L Lei; Theodore S Lawrence
Journal:  Cancer Res       Date:  2019-05-17       Impact factor: 12.701

2.  Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants.

Authors:  Danielle Hutchings; Zhengdong Jiang; Michael Skaro; Matthew J Weiss; Christopher L Wolfgang; Martin A Makary; Jin He; John L Cameron; Lei Zheng; David S Klimstra; Randall E Brand; Aatur D Singhi; Michael Goggins; Alison P Klein; Nicholas J Roberts; Ralph H Hruban
Journal:  Mod Pathol       Date:  2019-07-08       Impact factor: 7.842

3.  SPOP regulates the DNA damage response and lung adenocarcinoma cell response to radiation.

Authors:  Yiping Dong; Dan Zhang; Mengjiao Cai; Zhenzhen Luo; Yue Zhu; Liuyun Gong; Yutiantian Lei; Xinyue Tan; Qing Zhu; Suxia Han
Journal:  Am J Cancer Res       Date:  2019-07-01       Impact factor: 6.166

4.  Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma.

Authors:  Koji Shindo; Jun Yu; Masaya Suenaga; Shahriar Fesharakizadeh; Christy Cho; Anne Macgregor-Das; Abdulrehman Siddiqui; P Dane Witmer; Koji Tamura; Tae Jun Song; Jose Alejandro Navarro Almario; Aaron Brant; Michael Borges; Madeline Ford; Thomas Barkley; Jin He; Matthew J Weiss; Christopher L Wolfgang; Nicholas J Roberts; Ralph H Hruban; Alison P Klein; Michael Goggins
Journal:  J Clin Oncol       Date:  2017-08-02       Impact factor: 44.544

Review 5.  ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications.

Authors:  Samantha A Armstrong; Christopher W Schultz; Ariana Azimi-Sadjadi; Jonathan R Brody; Michael J Pishvaian
Journal:  Mol Cancer Ther       Date:  2019-11       Impact factor: 6.261

Review 6.  The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go.

Authors:  Elizabeth D Thompson; Nicholas J Roberts; Laura D Wood; James R Eshleman; Michael G Goggins; Scott E Kern; Alison P Klein; Ralph H Hruban
Journal:  Mod Pathol       Date:  2020-07-23       Impact factor: 7.842

Review 7.  Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy.

Authors:  Rille Pihlak; Jamie M J Weaver; Juan W Valle; Mairéad G McNamara
Journal:  Cancers (Basel)       Date:  2018-01-12       Impact factor: 6.639

8.  ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer.

Authors:  Yiannis Drosos; David Escobar; Ming-Yi Chiang; Kathryn Roys; Virginia Valentine; Marc B Valentine; Jerold E Rehg; Vaibhav Sahai; Lesa A Begley; Jianming Ye; Leena Paul; Peter J McKinnon; Beatriz Sosa-Pineda
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

9.  Comparative Proton and Photon Irradiation Combined with Pharmacological Inhibitors in 3D Pancreatic Cancer Cultures.

Authors:  Josephine Görte; Elke Beyreuther; Erik H J Danen; Nils Cordes
Journal:  Cancers (Basel)       Date:  2020-10-31       Impact factor: 6.639

10.  Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models.

Authors:  Charles R Dunlop; Yann Wallez; Timothy Isaac Johnson; Sandra Bernaldo de Quirós Fernández; Stephen T Durant; Elaine B Cadogan; Alan Lau; Frances M Richards; Duncan I Jodrell
Journal:  Br J Cancer       Date:  2020-08-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.